Runzhang Venture Capital
润璋创投
elsewhere's corpus covers Runzhang Venture Capital (润璋创投) only in passing — there's no dedicated profile of the fund. What does appear: it's an existing shareholder in Yangli Pharma, the innovative drug developer that closed a nine-figure RMB Series B led by Qiming Venture Partners in late 2025, alongside Taifu Capital and Hangzhou state capital ; and in December 2025 it joined the follow-on group in AllinkBio's nearly $50 million Series A extension, per BlueRun Ventures' account, alongside BlueRun, Yuansheng Venture Capital, 5Y Capital, and Longpan Investment . Beyond these co-investor mentions in partner-published round announcements, elsewhere has no material on the fund's background, size, or strategy.
AI-generated — may contain errors, please verify.
Coverage
AllinkBio Closes Nearly $50 Million Series A Extension, BlueRun Ventures Continues to Double Down | BlueRun Family
Accelerating Clinical Development at Full Speed
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 40, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Yangli Pharma closes nine-figure RMB Series B round led by Qiming Venture Partners
Focused on developing first-in-class and best-in-class Class 1 innovative drugs with global intellectual property rights, with a focus on oncology and chronic disease therapeutics.
